Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its 2020 fiscal year (FY20) and fourth quarter (4QFY20) ended August 31, 2020.
DILIsym Plays Critical Role in Submission to State of California for Common Analgesic Carcinogenicity Risk
Comments Submitted to California’s OEHHA Featured DILIsym Simulations
Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2020 Earnings Release and Conference Call
Conference Call to be on Monday, November 16, 2020, at 4:15 PM ET
First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA Review
FDA Review Cites DILIsym Results as Part of Turalio® Submission
Simulations Plus Releases GastroPlus® Version 9.8
Pharmaceutical researchers can confirm much more than just their “gut instinct” with enhancements to all validated non-oral delivery route models
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals...
Simulations Plus Teams Up with the University of Health Sciences and Pharmacy in St. Louis to Secure New Grant Award from the U.S. FDA
Partnership will develop and validate unique in vitro/in silico models for oral cavity products
Simulations Plus Extends Partnership with Large Pharmaceutical Company to Further Expand High-Throughput PBPK Capabilities in ADMET Predictor®
Improvements Establish HTPK Simulation Module as Key Gateway for Lead Compound Selection
Simulations Plus Partners with Large Pharmaceutical Company to Validate AI-Driven Drug Design Capabilities in ADMET Predictor®
New AIDD Module applied to active therapeutic program to provide lead optimization support
Simulations Plus Releases ADMET Predictor® Version 10.0 (APX)
New artificial intelligence-driven drug design functionality offers scientists unrivaled methods for lead optimization
FDA Review of Approved Drug, Ubrogepant, Included DILIsym Simulations
FDA Review Document and New Toxicological Sciences Publication Detail Results
Simulations Plus to Present at the LD 500 Virtual Conference
Simulations Plus, Inc. (Nasdaq: SLP), the premier provider of simulation and modeling software and consulting services for pharmaceutical...
Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and..
Simulations Plus Announces Pricing of $100 Million Underwritten Offering of Common Stock
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products...
Simulations Plus Announces Proposed Underwritten Public Offering
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and...
Simulations Plus Reports Third Quarter FY2020 Financial Results
Third Quarter and 9MoFY20 Revenues Grow 24%
Simulations Plus Sets Date for 3rd Quarter 2020 Earnings Release and Conference Call
Conference Call to be on Thursday, July 9, 2020, at 4:15 PM ET
Simulations Plus Receives New Grant Award from the FDA
Novel PBPK/PD modeling strategies for ophthalmic drug products will inform regulatory decision-making
Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus to Present at 17th Annual Craig-Hallum Institutional Investor Conference